WO2000039275A3 - Multiple shear stress responsive elements (ssre) and methods of use thereof - Google Patents

Multiple shear stress responsive elements (ssre) and methods of use thereof Download PDF

Info

Publication number
WO2000039275A3
WO2000039275A3 PCT/IL1999/000702 IL9900702W WO0039275A3 WO 2000039275 A3 WO2000039275 A3 WO 2000039275A3 IL 9900702 W IL9900702 W IL 9900702W WO 0039275 A3 WO0039275 A3 WO 0039275A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
shear stress
ssre
responsive elements
stress responsive
Prior art date
Application number
PCT/IL1999/000702
Other languages
French (fr)
Other versions
WO2000039275A2 (en
Inventor
Nitzan Resnick
Original Assignee
Florence Medical Ltd
Nitzan Resnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/220,510 external-priority patent/US6440726B1/en
Application filed by Florence Medical Ltd, Nitzan Resnick filed Critical Florence Medical Ltd
Priority to EP99961261A priority Critical patent/EP1141266A4/en
Priority to AU17954/00A priority patent/AU1795400A/en
Priority to JP2000591168A priority patent/JP2002533113A/en
Publication of WO2000039275A2 publication Critical patent/WO2000039275A2/en
Publication of WO2000039275A3 publication Critical patent/WO2000039275A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

This invention provides expression vectors comprising multiple shear stress responsive elements and one or more genes of interest and methods of treating disorders related to or associated with vasculogenesis and/or angiogenesis conditions.
PCT/IL1999/000702 1998-12-24 1999-12-23 Multiple shear stress responsive elements (ssre) and methods of use thereof WO2000039275A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99961261A EP1141266A4 (en) 1998-12-24 1999-12-23 Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof
AU17954/00A AU1795400A (en) 1998-12-24 1999-12-23 Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof
JP2000591168A JP2002533113A (en) 1998-12-24 1999-12-23 Expression vector containing a plurality of shear stress response elements (SSREs) and a gene of interest, and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11386398P 1998-12-24 1998-12-24
US09/220,510 US6440726B1 (en) 1998-12-24 1998-12-24 Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment
US09/220,510 1998-12-24
US60/113,863 1998-12-24

Publications (2)

Publication Number Publication Date
WO2000039275A2 WO2000039275A2 (en) 2000-07-06
WO2000039275A3 true WO2000039275A3 (en) 2000-10-26

Family

ID=26811564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1999/000702 WO2000039275A2 (en) 1998-12-24 1999-12-23 Multiple shear stress responsive elements (ssre) and methods of use thereof

Country Status (4)

Country Link
EP (1) EP1141266A4 (en)
JP (1) JP2002533113A (en)
AU (1) AU1795400A (en)
WO (1) WO2000039275A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247714B2 (en) 2001-10-16 2007-07-24 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
JP5581485B2 (en) * 2007-03-22 2014-09-03 インダストリーアカデミック コーポレーション ファンデーション， ザ カトリックユニバーシティ オブ コリア New use of EC-SOD and manufacturing method thereof
CN109371046A (en) * 2018-09-29 2019-02-22 上海交通大学 A kind of induction type oxin-antitoxin element for thermophilic microorganism genetic manipulation
USD926199S1 (en) 2019-05-17 2021-07-27 Opsens, Inc. Display screen or portion thereof with graphical user interface
CN112656763B (en) * 2020-12-29 2022-07-15 吉林大学 Preparation method of drug-loaded nano-micelle based on shear force response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132264A0 (en) * 1997-04-08 2001-03-19 Nasa Production of functional proteins: balance of shear stress and gravity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RESNICK ET AL.: "Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element", PROC. NATL. ACAD. SCI. USA, vol. 90, May 1993 (1993-05-01), pages 4591 - 4595, XP002075319 *
SHYY ET AL.: "The cis-acting phorbol ester "12-0-tetradecanoylphorbol 13-acetate"-responsive element is involved in shear stress-induced monocyte chemotactic protein 1 gene expression", PROC. NATL. ACAD. SCI. USA, vol. 92, August 1995 (1995-08-01), pages 8069 - 8073, XP002928997 *

Also Published As

Publication number Publication date
WO2000039275A2 (en) 2000-07-06
EP1141266A2 (en) 2001-10-10
JP2002533113A (en) 2002-10-08
AU1795400A (en) 2000-07-31
EP1141266A4 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
DE69034135D1 (en) DNA constructs to activate and alter the expression of endogenous genes
WO1999033982A3 (en) Human genes and gene expression products i
WO1999038972A9 (en) Human genes and gene expression products ii
IL127897A0 (en) Hamster ef-1alpha transcriptional regulatory dna
IL112873A0 (en) Rapamycin-fkbp12 binding proteins their isolation and their use
ATE338127T1 (en) RIBONUCLEASE RESISTANT RNA PREPARATION AND ITS USE
YU53899A (en) Use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders
IL120582A0 (en) Analysis of gene expression by display of 3'-end restriction fragments of cDNA
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
DE69636453D1 (en) MODULATION OF THE ACTIVITY OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP)
WO1998018932A3 (en) Novel pesticidal toxins and nucleotide sequences which encode these toxins
DE60128149D1 (en) Putrescin-n-methyltransferasepromotor
DK0960192T3 (en) Synthetic polynucleotides
WO2000039275A3 (en) Multiple shear stress responsive elements (ssre) and methods of use thereof
IL159966A0 (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
WO2001040519A3 (en) Methods for identifying modulators for balance related disorders
FI961202A (en) Grb3-3 gene, its variants and their uses
HUP9904235A3 (en) Novel constructs and vectors for the targeted and inducible expression of genes
WO2000024768A3 (en) Genes integrating signal transduction pathways
WO1999031253A3 (en) Novel flea epoxide hydrolase nucleic acid molecules, proteins and uses thereof
PT86034A (en) CLONING AND USE OF THE TRANSMINASE GENE ILVE
ATE321143T1 (en) GENE EXPRESSION IN MONOCYTES AND MACROPHAGES
FR2743818B1 (en) DNA CONSTRUCTS AND EXPRESSION VECTORS DERIVED FROM THE VA RNA GENE OF ADENOVIRUS
WO2002006502A3 (en) Adenovirus vectors comprising introns
WO2001014519A3 (en) Methods and compositions for regulating developmental identity

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 17954

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 591168

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999961261

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999961261

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999961261

Country of ref document: EP